NCT02917369 Integrative Analysis of Large-cell Lung Cancer
| NCT ID | NCT02917369 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai 10th People's Hospital |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2016-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Integrative analysis of LCLC
Eligibility Criteria
Inclusion Criteria: * Age ≤ 75 years with histologically proven LCLC * No severe major organ dysfunction * World Health Organization (WHO) performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * WHO performance status of \>1 * Prior cancer chemotherapy
Contact & Investigator
Da Fu, PhD
PRINCIPAL INVESTIGATOR
Shanghai 10th People's Hospital
Frequently Asked Questions
Who can join the NCT02917369 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02917369 currently recruiting?
Yes, NCT02917369 is actively recruiting participants. Contact the research team at fu800da900@126.com for enrollment information.
Where is the NCT02917369 trial being conducted?
This trial is being conducted at Ganzhou, China, Shanghai, China, Shanghai, China.
Who is sponsoring the NCT02917369 clinical trial?
NCT02917369 is sponsored by Shanghai 10th People's Hospital. The principal investigator is Da Fu, PhD at Shanghai 10th People's Hospital. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.